2021-04-10 5. 城上城行政中心2F 第三會議室
時間主題講者座長摘要簡報
14:00 ~ 14:20
瀏覽海報時間
All
鍾孝仁,
馮思中
14:20 ~ 14:24
MP01-1: Immunotherapy with checkpoint inhibitors improves survival in patients with metastatic urothelial carcinoma
吳芃諺
鍾孝仁,
馮思中
14:24 ~ 14:28
MP01-2: Inherited variants of adiponectin and its receptors are associated with the time to castration-resistant prostate cancer
張哲維
鍾孝仁,
馮思中
14:28 ~ 14:32
MP01-3: Docetaxel rechallenge improves survival in patients with metastatic castration-resistant prostate cancer: A retrospective study
吳芃諺
鍾孝仁,
馮思中
14:32 ~ 14:36
MP01-4: Management of adverse events in patients with metastatic renal cell carcinoma receiving second-line targeted therapy: Real-world experience in Taiwan
鍾孝仁
鍾孝仁,
馮思中
14:36 ~ 14:40
MP01-5: Combination of prostate health index with mpMRI for better assessment of true tumor boundary in prostate cancer
李宗叡
鍾孝仁,
馮思中
14:40 ~ 14:44
MP01-6: Perioperative and long-term oncological outcomes of patients with muscle invasive bladder cancer who underwent radical cystectomy: A single-center experience
曾文歆
鍾孝仁,
馮思中
14:44 ~ 14:48
MP01-7: The role of PD-L1 and Ki-67 in upper tract urothelial carcinoma
蔡牧堯
鍾孝仁,
馮思中
14:48 ~ 14:52
MP01-8: Combination of trans-perineal MRI– ultrasound fusion and template-guided mapping biopsy for prostate cancer diagnosis
胡蔚祥
鍾孝仁,
馮思中
14:52 ~ 14:56
MP01-9: Geriatric nutritional risk index as a prognostic marker for patients with metastatic castration resistant prostate cancer receiving docetaxel
謝享宸
鍾孝仁,
馮思中
14:56 ~ 15:00
MP01-10: Neoadjuvant immunotherapy as nivolumab and ipilimumab for muscle invasive urothelial bladder cancer: Preliminary report of single hospital
莊毓峰
鍾孝仁,
馮思中